Annual Chapter Symposium
Latest in Cardiology from ACC.org
- MAPLE-HCM: Aficamten Monotherapy vs. Metoprolol Monotherapy in Patients With Symptomatic Obstuctive HCMAficamten monotherapy was superior to metoprolol monotherapy in improving peak oxygen uptake and hemodynamics and decreasing symptoms among patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to results from the MAPLE-HCM trial...
- ODYSSEY-HCM: Mavacamten vs. Placebo in Patients With Symptomatic Nonobstructive HCMMavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), based on findings from the ODYSSEY-HCM trial...
- DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized For Acute HFIn-hospital initiation of dapagliflozin in patients hospitalized for acute heart failure (HF) did not significantly reduce the short-term risk of worsening HF or death, based on findings from the DAPA ACT HF-TIMI 68 trial presented at ESC Congress 2025.
- ACC Practice Made Perfect: The Second Skillset: The Business of CardiologyWelcome to The Second Skillset podcast series! In this second episode, our panelists discuss why understanding the business side of cardiovascular care is essential for today’s clinicians. The conversation explores how physicians can begin developing these non-clinical skills, why they matter for patient care and professional growth, and practical ways to get started.
- New ESC Guidance Issued on Lipids, Pregnancy, Valve Disease, Mental Health and MoreNew and revised clinical guidance spanning dyslipidemia, cardiovascular disease in pregnancy, valvular heart disease, myocarditis and pericarditis, and mental health was released as part of ESC Congress 2025 in Madrid.